Shares Of Esperion Tumbled 48% After End-Of-Phase-2 Meeting With FDA
September 29, 2015 at 20:56 PM EDT
The release of the minutes of Esperion's meeting with the FDA showed that the company still has a long road before it can bring its cholesterol drug to market.
